LYEL
Lyell Immunopharma, Inc.
9.26
2 x 6.74
2 x 11.92
bid
ask
-
0.15
1.59%
2 @ 05:49 AM
9.30 +0.04 (0.43%)
Ytd-69.92%
1y-47.83%
9.22
day range
9.56
9.21
52 week range
45.00
Open9.55Prev Close9.41Low9.22High9.56Mkt Cap226.92M
Vol111.39KAvg Vol149.82KEPS-12.86P/EN/AForward P/E-0.73
Beta-0.03Short Ratio6.15Inst. Own58.79%DividendN/ADiv YieldN/A
Ex Div DateN/AEarning11-0650-d Avg12.93200-d Avg18.981yr Est1.00
Income Statement
Total Revenue4.00K
Revenues (USD)4.00K
Gross Profit4.00K
Operating Expenses47.34M
Research and Development Expense39.52M
Selling, General and Administrative Expense9.58M
Operating Income-47.34M
Net Income-44.75M
Net Income Common Stock-44.75M
Net Income Common Stock (USD)-44.75M
Consolidated Income-44.75M
Earnings per Basic Share-1.92
Earnings per Basic Share (USD)-1.92
Earnings per Diluted Share-1.92
Earning Before Interest & Taxes (EBIT)-44.75M
Earning Before Interest & Taxes (USD)-44.75M
Weighted Average Shares23.36M
Weighted Average Shares Diluted23.36M
Balance Sheet
Cash and Equivalents74.57M
Cash and Equivalents (USD)74.57M
Investments174.01M
Investments Current131.12M
Investments Non-Current42.90M
Current Assets213.54M
Property, Plant & Equipment Net47.29M
Total Assets311.15M
Total Debt36.93M
Current Liabilities39.87M
Debt Non-Current36.93M
Total Liabilities77.34M
Accumulated Retained Earnings (Deficit)-1.69B
Accumulated Other Comprehensive Income-158.00K
Shareholders Equity233.82M
Shareholders Equity (USD)233.82M
Assets Non-Current97.61M
Total Debt (USD)36.93M
Liabilities Non-Current37.47M
Trade and Non-Trade Payables3.88M
Cash Flow
Depreciation, Amortization & Accretion2.22M
Net Cash Flow from Financing522.00K
Net Cash Flow / Change in Cash & Cash Equivalents-17.78M
Capital Expenditure-251.00K
Issuance (Purchase) of Equity Shares522.00K
Net Cash Flow from Investing15.62M
Net Cash Flow - Investment Acquisitions and Disposals15.87M
Net Cash Flow from Operations-33.92M
Share Based Compensation4.53M